Published in J Hypertens on February 01, 2001
Pharmacy Implementation Trial: Adherence to Antihypertensive Therapy | NCT00460343
Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ (2008) 3.24
The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract (2007) 2.51
Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther (2010) 2.31
Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J (2008) 1.44
Intensifying therapy for hypertension despite suboptimal adherence. Hypertension (2009) 1.22
The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol (2002) 1.21
Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr (2013) 1.03
All that glisters is not gold: a comparison of electronic monitoring versus filled prescriptions--an observational study. BMC Health Serv Res (2006) 1.00
Adherence: a review of education, research, practice and policy in Switzerland. Pharm Pract (Granada) (2009) 0.94
Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol (2007) 0.93
Cultural adaptation of a compliance questionnaire for patients with rheumatoid arthritis to a Korean version. Korean J Intern Med (2011) 0.93
Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. J Behav Med (2005) 0.92
A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens (2008) 0.91
An Electronic Adherence Measurement Intervention to Reduce Clinical Inertia in the Treatment of Uncontrolled Hypertension: The MATCH Cluster Randomized Clinical Trial. J Gen Intern Med (2016) 0.90
Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med (2010) 0.90
Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol (2015) 0.90
The Effectiveness of Medication Adherence Interventions Among Patients With Coronary Artery Disease: A Meta-analysis. J Cardiovasc Nurs (2016) 0.89
Effect of partial compliance on cardiovascular medication effectiveness. Heart (2002) 0.88
Developing a generic, individualised adherence programme for chronic medication users. Pharm Pract (Granada) (2008) 0.88
Medication adherence and resistant hypertension. J Hum Hypertens (2014) 0.87
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine. J Child Adolesc Psychopharmacol (2010) 0.87
Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care. Scand J Prim Health Care (2007) 0.85
Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin Res Cardiol (2016) 0.81
Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. BMC Cardiovasc Disord (2006) 0.80
Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens (2015) 0.80
Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol (2016) 0.80
Interdisciplinary Medication Adherence Program: The Example of a University Community Pharmacy in Switzerland. Biomed Res Int (2016) 0.77
Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. J Am Heart Assoc (2016) 0.76
Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension. Vasc Health Risk Manag (2007) 0.76
Current Situation of Medication Adherence in Hypertension. Front Pharmacol (2017) 0.75
Pattern of timing adherence could guide recommendations for personalized intake schedules. J Pers Med (2012) 0.75
Medicine partnerships. Heart (2003) 0.75
Antihypertensive treatment and compliance. Non-adherence should be addressed first. BMJ (2001) 0.75
Immunosuppressive therapy after solid-organ transplantation: does the INTERMED identify patients at risk of poor adherence? Pharm Pract (Granada) (2016) 0.75
Overview of resistant hypertension: A glimpse of the cardiologist's current standpoint. World J Cardiol (2012) 0.75
Are we satisfied with the follow-up of hypertensive and chronic kidney disease patients in outpatient clinics? Hippokratia (2011) 0.75
Understanding patient management: the need for medication adherence and persistence. Malays Fam Physician (2008) 0.75
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Molecular phylogeny of the New World monkeys (Platyrrhini, primates). Mol Phylogenet Evol (1993) 1.21
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest (2001) 1.13
Molecular genetics of spectral tuning in New World monkey color vision. J Mol Evol (1998) 1.13
Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J (1978) 1.12
DNA evidence on the phylogenetic systematics of New World monkeys: support for the sister-grouping of Cebus and Saimiri from two unlinked nuclear genes. Mol Phylogenet Evol (1995) 1.11
Isolated office hypertension: a prehypertensive state? J Hypertens (1996) 1.11
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension (2000) 1.11
Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension (1986) 1.05
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol (1973) 1.05
Renin as a risk factor in essential hypertension: more evidence. Am J Med (1973) 1.04
Aldosterone excretion. Physiological variations in man measured by radioimmunoassay or double-isotope dilution. Circ Res (1972) 1.04
Compliance with antihypertensive therapy. Clin Exp Hypertens (1999) 1.03
NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab (2001) 1.01
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther (1992) 0.99
Simultaneous ipsilateral and contralateral measurements of vasomotion in conduit arteries of human upper limbs. Am J Physiol (1995) 0.98
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A (2000) 0.98
Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation (1991) 0.98
Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol (1999) 0.98
Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med (1977) 0.97
Rational use of captopril. Lancet (1979) 0.97
The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am J Med (1975) 0.97
Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract (1999) 0.96
Discontinuation of chronic haemodialysis after control of arterial hypertension; long term follow-up. Proc Eur Dial Transplant Assoc (1983) 0.96
Effect of atriopeptin III on hematocrit and volemia of nephrectomized rats. Am J Physiol (1986) 0.96
Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol (1982) 0.96
Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension (1988) 0.95
Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. Clin Phys Physiol Meas (1991) 0.95
Confocal microscopy to analyze cytosolic and nuclear calcium in cultured vascular cells. Am J Physiol (1994) 0.95
Effect of nadolol in treatment of hypertension. J Clin Pharmacol (1979) 0.95
Salt- and angiotensin II-dependent variations in amiloride-sensitive rectal potential difference in mice. Clin Exp Pharmacol Physiol (2000) 0.94
Fetal globin expression in New World monkeys. J Biol Chem (1996) 0.94
The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. Eur Heart J (1983) 0.94
Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int (1996) 0.94
Self poisoning with enalapril. Br Med J (Clin Res Ed) (1984) 0.93
How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol (2000) 0.93
Molecular phylogeny of the New World monkeys (Platyrrhini, primates) based on two unlinked nuclear genes: IRBP intron 1 and epsilon-globin sequences. Am J Phys Anthropol (1996) 0.93
Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations. Biochemistry (1997) 0.93
Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med (1976) 0.92
Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. Hypertension (1982) 0.92
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension (1993) 0.91
Endothelial function in congestive heart failure. Am Heart J (1993) 0.91
Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. Prog Biochem Pharmacol (1976) 0.91
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension (1999) 0.91
Unidirectional and oscillatory shear stress differentially modulate NOS III gene expression. Nitric Oxide (2000) 0.91
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension (1995) 0.91
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol (1987) 0.91
Blood pressure recording in the ambulatory patient and evaluation of cardiovascular risk. Clin Sci (Lond) (1985) 0.90
Lithium infusion to study sodium handling in unanesthetized hypertensive rats. Hypertension (1986) 0.90
Plasma aldosterone-renin interrelationships in various forms of essential hypertension. Studies using a rapid assay of plasma aldosterone. Am J Cardiol (1973) 0.90
True versus immunoreactive angiotensin II in human plasma. Hypertension (1985) 0.90
[Inhibition of plasmatic renin activity by potassium]. J Urol Nephrol (Paris) (1968) 0.90
Changes in treatment during and after hospitalization in patients taking drugs for cardiovascular diseases. Cardiovasc Drugs Ther (1996) 0.90
Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA (1977) 0.90
Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med (1984) 0.90
Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther (1986) 0.89
A device for subjecting vascular endothelial cells to both fluid shear stress and circumferential cyclic stretch. Ann Biomed Eng (1995) 0.89
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol (1995) 0.89
Plasma bradykinin levels in human chronic congestive heart failure. Clin Sci (Lond) (2000) 0.89